Background: Previous studies showed that patients with Severe IBS respond better to fecal microbiota transplantation (FMT) than do those with Moderate IBS.

Aims: The present study aimed to determine the effects of the transplant dose, route of administering it and repeating FMT on this difference.

Methods: This study included 186 patients with IBS randomized 1:1:1 into groups with a 90-g transplant administered once to the colon (LI), once to the duodenum (SI), or twice to the distal duodenum twice (repeated SI). The patients provided a fecal sample and were asked to complete three questionnaires at baseline and at 3, 6, and 12 months after FMT. The fecal bacteria composition and Dysbiosis index were analyzed using 16 S rRNA gene PCR DNA amplification/probe hybridization covering regions V3-V9.

Results: There was no difference in the response rates between severe IBS and moderate IBS for SI and repeated SI at all observation intervals after FMT. In the LI group, the response rate at 3 months after FMT was higher for moderate IBS than for severe IBS. The levels of Dorea spp. were higher and those of Streptococcus salivarius subsp. Thermophilus, Alistipes spp., Bacteroides and Prevotella spp., Parabacteroides johnsoni and Parabacteroides spp. were lower in moderate IBS than in severe IBS.

Conclusions: There was no difference in the response to FMT between severe and moderate IBS when a 90-g transplant was administered to the small intestine. The difference in the bacterial profile between severe and moderate IBS may explain the difference in symptoms between these patients. ( www.

Clinicaltrials: gov : NCT04236843).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11026185PMC
http://dx.doi.org/10.1007/s10620-024-08369-xDOI Listing

Publication Analysis

Top Keywords

moderate ibs
20
difference response
12
severe moderate
12
severe ibs
12
ibs
10
fecal microbiota
8
microbiota transplantation
8
patients severe
8
90-g transplant
8
transplant administered
8

Similar Publications

Laboratory changes during dupilumab treatment for atopic dermatitis.

Actas Dermosifiliogr

January 2025

Dermatology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Introduction: Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.

The Objective: of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.

View Article and Find Full Text PDF

Systematic Review: Integrated Models of Care for Managing Irritable Bowel Syndrome.

Neurogastroenterol Motil

January 2025

Faculty of Medicine, Centre for Health Services Research, Centre for Online Health, The University of Queensland, Woolloongabba, Queensland, Australia.

Article Synopsis
  • Integrated models of care for irritable bowel syndrome (IBS) show promise in enhancing symptoms and overall quality of life for adults with the condition.
  • A review of 16 studies revealed that most integrated models involved collaboration among various healthcare professionals and utilized non-pharmacological therapies, yielding significant improvements in IBS symptoms and quality of life.
  • Digital health tools, such as telephone coaching and online modules, were incorporated in some models, showcasing the adaptability of care delivery methods in managing IBS.
View Article and Find Full Text PDF

Objectives: Hearing aids (HAs) are a widely accepted first-line treatment option for individuals suffering from both hearing loss and chronic tinnitus. Though HAs are highly effective at improving speech understanding, their effectiveness in ameliorating tinnitus symptoms is less clear. In recent years, several investigators have reported on attempts to predict HAs effectiveness on tinnitus symptoms using an array of variables.

View Article and Find Full Text PDF

OX40: A promising therapeutic target in moderate-to-severe atopic dermatitis.

Actas Dermosifiliogr

December 2024

Servicio de Dermatología, Hospital Universitario San Cecilio, Granada. Instituto Biosanitario de Granada (ibs.GRANADA), Spain. Electronic address:

View Article and Find Full Text PDF

Shape-memory materials are widely utilized in biomedical devices and tissue engineering, particularly for their ability to undergo predefined shape changes in response to external stimuli. In this study, a shape-transformable organohydrogel was developed by incorporating a gallium mesh into a polyacrylamide/alginate/glycerol matrix. The gallium mesh, which transitions between solid and liquid states at moderate temperatures (~29.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!